Promedior, Inc. announced Thursday the successful completion of its previously announced sale to Roche (SIX: RO, ROG;OTCQX: RHHBY). With this acquisition, Roche obtained full rights to Promedior’s entire portfolio of molecules for serious fibrotic diseases, notably PRM-151. Under the terms of the merger agreement, Roche made an upfront cash payment of USD 390 million, with additional contingent payments of up to USD 1 billion to be made based on the achievement of certain predetermined development, regulatory and commercial milestones.
Read the full article: Promedior Announces Completion of Acquisition by Roche //
Source: https://www.prnewswire.com/news-releases/promedior-announces-completion-of-acquisition-by-roche-301004662.html